View Older Stories
-
Artivion (AORT) Tops Q1 EPS by 4c ; Offers Guidance
-
Freedom Capital Markets Starts Artivion Inc. (AORT) at Buy
-
Ladenburg Thalmann Upgrades Artivion Inc. (AORT) to Buy
-
Needham stays Buy on Artivion Inc. (AORT) amid NEXUS FDA approval
-
Stifel on Artivion Inc. (AORT): NEXUS FDA approval a clear positive
-
Artivion gets FDA approval for NEXUS aortic arch system, considers acquisition
-
Artivion (AORT) Reiterated at Buy by Stifel After Physician Conversations
-
Artivion Inc. (AORT) PT Lowered to $48 at Canaccord Genuity
-
Artivion (AORT) Tops Q4 EPS by 11c
-
Oppenheimer Reiterates Outperform Rating on Artivion Inc. (AORT)
-
Artivion presents clinical trial data at thoracic surgery meeting
-
Canaccord Genuity Reiterates Buy Rating on Artivion Inc. (AORT)
-
Artivion Inc. (AORT) PT Raised to $50 at Oppenheimer
-
Artivion Inc. (AORT) PT Raised to $58 at Needham
-
Artivion (AORT) Tops Q3 EPS by 13c ; Offers Guidance
-
Artivion presents positive AMDS trial data at European cardiac surgery meeting
-
Citizens Lifts Artivion (AORT) PT to $47 on Pipeline Strength, Growth Outlook
-
Artivion agrees to purchase two Austin buildings for $20.5 million
-
Artivion Inc. (AORT) PT Raised to $50 at Canaccord Genuity
-
Artivion Inc. (AORT) PT Raised to $46 at Stifel
-
Artivion Inc. (AORT) PT Raised to $50 at Needham
-
Ladenburg Thalmann Downgrades Artivion Inc. (AORT) to Neutral
-
Artivion Inc. (AORT) PT Raised to $40 at Stifel
-
Artivion Inc. (AORT) PT Raised to $45 at Needham
-
Artivion Inc. (AORT) PT Raised to $41 at Canaccord Genuity
-
Artivion Inc. (AORT) PT Lowered to $40 at Oppenheimer
-
Artivion Inc. (AORT) PT Raised to $40 at Oppenheimer
-
Artivion Inc. (AORT) PT Raised to $42 at Citizens JMP
-
Artivion (AORT) Tops Q2 EPS by 24c ; Offers Guidance
-
Artivion Inc. (AORT) PT Raised to $36 at Stifel
-
Citizens JMP Reiterates Market Outperform Rating on Artivion Inc. (AORT)
-
Canaccord Genuity Starts Artivion Inc. (AORT) at Buy
-
Artivion (AORT) Announces Agreements to Exchange $95M in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock
-
Citizens JMP Reiterates Market Outperform Rating on Artivion Inc. (AORT)
-
Stifel Reiterates Buy Rating on Artivion Inc. (AORT)
-
Artivion (AORT) Tops Q1 EPS by 6c ; Offers Guidance
-
Artivion Inc. (AORT) PT Lowered to $30 at Stifel
-
Artivion Inc. (AORT) PT Lowered to $32 at Needham
-
Citizens JMP Reiterates Market Outperform Rating on Artivion Inc. (AORT)
-
Artivion (AORT) Tops Q4 EPS by 6c, provides guidance
-
Oppenheimer Reiterates Outperform Rating on Artivion Inc. (AORT)
-
Oppenheimer Reiterates Outperform Rating on Artivion Inc. (AORT)
-
Artivion (AORT) Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis
-
Artivion (AORT) is taking measures to address a cybersecurity incident
-
Artivion Inc. (AORT) PT Raised to $34 at Needham
-
Artivion (AORT) Tops Q3 EPS by 18c, Beats on Revenue; Offers FY24 Revenue Guidance
-
JMP Securities Starts Artivion Inc. (AORT) at Market Outperform
-
Artivion (AORT) Announces Presentation of Late-Breaking Clinical Data at EACTS
-
Needham Reiterates Buy Rating on Artivion Inc. (AORT)
-
Artivion Inc. (AORT) PT Raised to $30 at Oppenheimer

